Recent studies have found the involvement of NFE2L2 pathway inhibition by the mtROS in the evolution of Chagas cardiomyopathy, and enhancing the same pathway is currently being studied as one of the potential therapeutic options. Here, NFE2L2 is linked to Chagas cardiomyopathy.